Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402581 | 0.85 | ANO1 (0.60) | ANO1P2RX4SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL29029229 | 0.83 | ANO1 (0.53) | ANO1P2RX4SMN1; SMN2MAPTNOD2 | |
| SCHEMBL30402922 | 0.83 | ANO1 (0.61) | ANO1P2RX4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25371024 | 0.78 | P2RX4 (0.63) | ANO1P2RX4SMN1; SMN2ALDH1A1 | |
| SCHEMBL30368210 | 0.76 | ANO1 (0.65) | ANO1P2RX4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25373339 | 0.75 | P2RX4 (0.73) | ANO1P2RX4SMN1; SMN2ALDH1A1 | |
| SCHEMBL24173293 | 0.73 | SMN1; SMN2 (0.67) | ANO1P2RX4SMN1; SMN2NOD2ALDH1A1 | |
| SCHEMBL30403121 | 0.73 | ALDH1A1 (0.50) | ANO1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL31306247 | 0.73 | ANO1 (1.00) | ANO1 | |
| SCHEMBL21198539 | 0.73 | ANO1 (1.00) | ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |